(Q39778480)

14 September 2017

Genetic immunotherapy of lung cancer using conditionally replicating adenovirus and adenovirus-interferon-beta (English)

1 reference

14 September 2017

1 reference

1 reference

M-Y Park

1

1 reference

14 September 2017

D R Kim

2

1 reference

14 September 2017

H W Jung

3

1 reference

14 September 2017

H-I Yoon

4

1 reference

14 September 2017

J H Lee

5

1 reference

14 September 2017

C-T Lee

6

1 reference

14 September 2017

6 November 2009

1 reference

14 September 2017

1 reference

14 September 2017

17

1 reference

14 September 2017

5

1 reference

14 September 2017

356-364

1 reference

https://scigraph.springernature.com/pub.10.1038/cgt.2009.78

14 September 2017

0 references

cites work

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.78

A phase I study of vaccination with autologous, irradiated melanoma cells engineered to secrete human granulocyte-macrophage colony stimulating factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.78

Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.78

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.78

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.78

Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.78

A tumor-specific conditionally replicative adenovirus vector expressing TRAIL for gene therapy of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.78

In vitro and in vivo activities of an oncolytic adenoviral vector designed to express GM-CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.78

Potent antitumor activity of oncolytic adenovirus expressing mda-7/IL-24 for colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.78

Immune gene-viral therapy with triplex efficacy mediated by oncolytic adenovirus carrying an interferon-gamma gene yields efficient antitumor activity in immunodeficient and immunocompetent mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.78

Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.78

Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.78

Combination therapy with conditionally replicating adenovirus and replication defective adenovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.78

In vivo imaging of adenovirus transduction and enhanced therapeutic efficacy of combination therapy with conditionally replicating adenovirus and adenovirus-p27.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.78

Intrapulmonary IFN-beta gene therapy using an adenoviral vector is highly effective in a murine orthotopic model of bronchogenic adenocarcinoma of the lung.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.78

Interferon-beta gene therapy for cancer: basic research to clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.78

A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.78

Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.78

Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.78

Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.78

Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.78

Replication properties of human adenovirus in vivo and in cultures of primary cells from different animal species

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.78

Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.78

Combination effect of oncolytic adenovirotherapy and TRAIL gene therapy in syngeneic murine breast cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.78

Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.78

Assessment of a combined, adenovirus-mediated oncolytic and immunostimulatory tumor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.78

Treatment of cancer with a novel dual-targeted conditionally replicative adenovirus armed with mda-7/IL-24 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.78

CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor--armed oncolytic adenovirus for the treatment of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.78

Linked tumor-selective virus replication and transgene expression from E3-containing oncolytic adenoviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.78

Gene therapy for lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.78

inferred from DOI database lookup

7 January 2021

based on heuristic

Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.78

inferred from DOI database lookup

7 January 2021

based on heuristic

An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.78

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/CGT.2009.78

1 reference

14 September 2017

1 reference